• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Disease Prevention and Control, San Francisco Department of Public HealthPopulation Health Division SF Department of Public HealthPopulation Health Division SF Department of Public Health

  • Infectious Diseases A to Z
  • About
  • Contact
  • Home
  • Communicable Disease
    • 24/7 Disease Reporting
      • Disease Reporting: Additional Information for Medical Providers
      • Influenza Reporting
      • Frequently Requested Phone Numbers 
    • Healthy Habits
      • How to Put on and Remove a Face Mask 
    • Publications, Data, and Reports
    • Infection Control
      • Infection Prevention and Control for Health Care Settings
      • Infection Prevention and Control for Long-Term Care Facilities
    • Infectious Diseases A to Z
  • Immunizations
    • Vaccines You Need
      • Adults
      • Children & Adolescents
      • Vaccines for Gay and Bisexual Men
    • Where to Get Immunized
    • Influenza (Flu)
    • Vaccine Safety
    • Immunization Programs
      • Flu Vaccine Programs: Ordering Information for Health Care Providers
      • Hepatitis Programs
        • Hepatitis Education
        • Hepatitis Vaccine Distribution Program
        • Perinatal Hep B Program
        • Programs for Asian and Pacific Islanders
      • California Immunization Registry (CAIR)
      • Vaccines for Children
      • San Francisco Immunization Coalition
      • Emergency Mass Prophylaxis Clinic Planning
    • Schools and Child Care
    • Resources & Materials
      • Vax Facts: Vaccine Updates
      • Immunization Links
      • Request Materials
      • Vaccine Management Plan
    • Information for Medical Providers
    • Provider Spotlight
  • AITC Immunization & Travel Clinic
    • International Travelers
      • Promoting Travelers’ Health
      • Yellow Fever Vaccine FAQ (Frequently Asked Questions)
    • Immunization & Testing
    • Services for Businesses
    • Contact, Location, Hours, and Payments
    • Plan Your Visit
    • Prices
      • Low-Cost or Free Vaccines at AITC
    • Forms
    • Links
    • About AITC
  • Health Alerts & Emergencies
    • Prepare
    • Health Alerts
      • Sign Up For Health Alerts
    • Infectious Disease Plan
      • Emergency Exercises
    • Clinician Emergency Guide
    • Recognizing Bioterrorism
    • Programs and Activities
  • Tuberculosis Control
    • Tuberculosis Services
    • Tuberculosis Information For Medical Providers
      • LTBI Referral (Specific to Civil Surgeons)
      • Tuberculosis Screening Guidelines
        • Tuberculosis Testing
      • Tuberculosis Clinic Referrals Criteria
      • Managing Positive Reactions
      • Suspected/Confirmed Active TB Reporting
      • LTBI Risk Assessment Tools and Treatment Guidelines
      • Hospital Discharge
      • QuantiFERON Information
      • Infection Control Guidelines
      • Shelter Client Screening Guidelines
      • TB Resources for the Public
    • Publications
    • Reports
    • Links
    • San Francisco Tuberculosis Prevention and Control Program (SFTBPCP) Supplemental Information
  • Public Health Laboratory
    • Laboratory Contact Information
    • Check COVID-19 and Influenza Test Results Online
    • Non-Diagnostic General Health Assessments (NGHA)
    • General Specimen Submission Guidelines
    • Forms for Specimen and Culture Submission
    • Laboratory Test Menu
  • STD Services
  • Infectious Diseases A to Z
  • About

TB Risk and Targeted Immunotherapy/Biologics Recommendations

SFDPH TB Clinic

TB Screening and Tumor Necrosis Factor (TNF)-Inhibitors or other Targeted Immunotherapies

December 2022

The use of new targeted immunotherapies (or biologics) has radically transformed the available treatment options for many chronic diseases. These targeted immunotherapies work by blocking specific molecules that mediate certain immune responses or by depleting the cells that express them. Some can also increase the risk of progression to active TB disease by downregulating the immunologic functions that contain TB organisms. This risk varies by drug class and mechanism of action1.

The use of tumor necrosis factor (TNF)-alpha inhibitors has been associated with high risk of progression of TB; active TB infection occurring in the setting of TNF-inhibitor use has a greater  likelihood of involving extra-pulmonary sites and of being disseminated at presentation compared with other TB cases2. The risk has been reported to be greater with infliximab and adalimumab than with etanercept2. Latent TB infection (LTBI) screening and treatment appears to significantly reduce the incidence of progression to active TB in these patients3.

There is growing evidence that other targeted immunotherapies (e.g., PD-1/PDL-1 inhibitors, CTLA-4 inhibitors, JAK kinase inhibitors, and IL-6 and IL-23 inhibitors to name a few) are also associated with increased risk of TB reactivation. These targeted immunotherapies should be treated similarly as for a TNF-inhibitor. Data is rapidly emerging in this area as more targeted immunotherapies are approved.  Based mostly on expert opinion, SFDPH recommends that patients with a diagnosis of LTBI should be initiated on treatment for at least 1 month, if possible, prior to starting those targeted immunotherapies where a risk for TB progression has been identified.

The Table lists some targeted immunotherapies where the manufacturer’s package insert recommends TB testing.  This list does not include all available targeted immunotherapies; check the manufacturer’s package insert for details.

Targeted Immunotherapies and TB Risk, 2022

University of California San Francisco TB Targeted Immunotherapy Workgroup*

TB testing with interferon-gamma release assay or tuberculin skin test is recommended for the following targeted immunotherapies (per the manufacturers drug insert)

Drug Name Mechanism/Target
Abatacept CTLA-4
Adalimumab TNF-alpha
Alemtuzumab CD-52
Atezolizumab PDL-1
Avelumab PDL-1
Baricitinib Janus kinase (JAK1/JAK2)
Basiliximab IL-2
Belatacept Selective T cell co-stimulation blocker
Brodalumab IL-17
Canakinumab IL-1B
Cemiplimab PD-1/PDL-1
Certolizumab TNF-alpha
Durvalumab PDL-1
Emapalumab Anti-IFN-gamma
Etanercept TNF-alpha and TNF-beta
Golimumab TNF-alpha
Guselkumab IL-23
Inebilizumab CD-19
Infliximab TNF-alpha
Ixekizumab IL-17
Pembrolizumab PD-1
Risankizumab IL-23
Ruxolitinib Janus kinase (JAK1/JAK2)
Sarilumab IL-6
Secukinumab IL-17
Tildrakizumab IL-23
Tocilizumab IL-6
Tofacitinib Janus kinase (JAK1/JAK2/JAK3)
Upadacinitib Janus kinase (JAK1)
Ustekinumab IL-12 and IL-23p40
Vedolizumab integrin (a4B7)
Abbreviations: CTLA-4, Cytotoxic T-lymphocyte associated protein 4; TNF, tumor-necrosis factor, PD-1, Programmed Death-1, PDL, Programmed Cell Death Ligand-1; IL, interleukin

*University of California San Francisco TB Targeted Immunotherapy Workgroup

  • Joel Ernst, MD, UCSF Division of Experimental Medicine
  • Annie Kim, Clinical Pharmacist, UCSF-San Francisco General Hospital
  • Janice Louie, MD, MPH, SFDPH TB Clinic and UCSF Division of Infectious Diseases
  • Daniel Minter, MD, UCSF Division of Infectious Diseases
  • Maria Laura Casalegno, MD, UCSF Division of Infectious Diseases
  • Matthew Murrill, MD, PhD, UCSF Department of Medicine
  • Allison Phillips, PhD, SFDPH TB Clinic
  • Jorge Salazar, MD, UCSF Division of Infectious Diseases
  • John Szumowski, MD, MPH, UCSF Division of HIV, ID & Global Medicine
  • Gustavo Velásquez, MD, MPH, UCSF Division of HIV, ID & Global Medicine

With special thanks to Pennan Barry, MD, MPH, California Department of Public Health and UCSF Division of Infectious Diseases and Jonathan Graf, MD, UCSF Division of Rheumatology for their input.

Print PDF: https://www.sfcdcp.org/wp-content/uploads/2022/12/SFDPH-TB-Clinic-TI-recommendationsDec2022.pdf

Primary Sidebar

Tuberculosis Control

  • Tuberculosis Services
    • Tuberculosis Testing Sites
  • Tuberculosis Information For Medical Providers
    • LTBI Referral (Specific to Civil Surgeons)
    • Tuberculosis Screening Guidelines
      • Tuberculosis Testing
    • Tuberculosis Clinic Referrals Criteria
    • Managing Positive Reactions
    • Suspected/Confirmed Active TB Reporting
    • LTBI Risk Assessment Tools and Treatment Guidelines
    • Hospital Discharge
    • QuantiFERON Information
    • Infection Control Guidelines
    • Shelter Client Screening Guidelines
    • TB Resources for Trainees
    • Sputum Collection for Primary Care Providers
    • Recommendations for Latent TB Infection Screening and Treatment during Pregnancy
    • TB Risk and Targeted Immunotherapy/Biologics Recommendations
  • TB Resources for the Public
  • Publications
  • Reports
  • Links
  • San Francisco Tuberculosis Prevention and Control Program (SFTBPCP) Supplemental Information

CMR Forms

Medical providers: download the Confidential Morbidity Report (CMR) form to report a communicable disease

CMR Form

or download the COVID-19 CMR form to report COVID-19 hospitalizations, deaths and POC testing by HCPs

COVID-19 CMR Form

Footer

Contact

SF Dept of Public Health
101 Grove Street
San Francisco, CA 94102
(415) 554-2500

Web Links

  • SF Dept. of Public Health
  • City and County of San Francisco

Privacy Policy | Sitemap | Contact Us
Website by MIGHTYminnow

© Copyright 1998 - 2023, Department of Public Health, City and County of San Francisco